
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6881594/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The Kappa Opioid Receptor and the Sleep of Reason: Cortico-Subcortical Imbalance Following Salvinorin-A. International Journal of Neuropsychopharmacology, 2022, 25, 54-63.	1.0	7
2	Ayahuasca as a Versatile Therapeutic Agent: From Molecules to Metacognition and Back. , 2021, , 1-19.		0
3	Dopamine modulations of rewardâ€driven music memory consolidation. Annals of the New York Academy of Sciences, 2021, 1502, 85-98.	1.8	17
4	Prospective examination of synthetic 5-methoxy-N,N-dimethyltryptamine inhalation: effects on salivary IL-6, cortisol levels, affect, and non-judgment. Psychopharmacology, 2020, 237, 773-785.	1.5	61
5	N,N-dimethyltryptamine compound found in the hallucinogenic tea ayahuasca, regulates adult neurogenesis in vitro and in vivo. Translational Psychiatry, 2020, 10, 331.	2.4	59
6	Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial. Psychological Medicine, 2019, 49, 655-663.	2.7	479
7	Dopamine modulates the reward experiences elicited by music. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 3793-3798.	3.3	186
8	Ayahuasca improves emotion dysregulation in a community sample and in individuals with borderline-like traits. Psychopharmacology, 2019, 236, 573-580.	1.5	48
9	Neoadjuvant Chemotherapy for Breast Cancer Treatment and the Evidence-Based Interaction with Immediate Autologous and Implant-Based Breast Reconstruction. Clinics in Plastic Surgery, 2018, 45, 25-31.	0.7	11
10	Four Weekly Ayahuasca Sessions Lead to Increases in "Acceptance―Capacities: A Comparison Study With a Standard 8-Week Mindfulness Training Program. Frontiers in Pharmacology, 2018, 9, 224.	1.6	66
11	Intrinsically regulated learning is modulated by synaptic dopamine signaling. ELife, 2018, 7, .	2.8	36
12	Validation of a Spanish version of the Schizotypal Personality Questionnaire (SPQ): Psychometric characteristics and underlying factor structure derived from a healthy university student sample. Actas Espanolas De Psiquiatria, 2018, 46, 159-73.	0.1	2
13	Cocaine addiction is associated with abnormal prefrontal function, increased striatal connectivity and sensitivity to monetary incentives, and decreased connectivity outside the human reward circuit. Addiction Biology, 2017, 22, 844-856.	1.4	37
14	Assessing the Psychedelic "After-Glow―in Ayahuasca Users: Post-Acute Neurometabolic and Functional Connectivity Changes Are Associated with Enhanced Mindfulness Capacities. International Journal of Neuropsychopharmacology, 2017, 20, 698-711.	1.0	111
15	The alkaloids of Banisteriopsis caapi, the plant source of the Amazonian hallucinogen Ayahuasca, stimulate adult neurogenesis in vitro. Scientific Reports, 2017, 7, 5309.	1.6	112
16	Non-demented Parkinson's disease patients with apathy show decreased grey matter volume in key executive and reward-related nodes. Brain Imaging and Behavior, 2017, 11, 1334-1342.	1.1	42
17	Population pharmacokinetic modelling of rupatadine solution in 6–11 year olds and optimisation of the experimental design in younger children. PLoS ONE, 2017, 12, e0176091.	1.1	7
18	The Endogenous Hallucinogen and Trace Amine N,N-Dimethyltryptamine (DMT) Displays Potent Protective Effects against Hypoxia via Sigma-1 Receptor Activation in Human Primary iPSC-Derived Cortical Neurons and Microglia-Like Immune Cells. Frontiers in Neuroscience, 2016, 10, 423.	1.4	64

#	Article	IF	CITATIONS
19	New World Tryptamine Hallucinogens and the Neuroscience of Ayahuasca. Current Topics in Behavioral Neurosciences, 2016, 36, 283-311.	0.8	37
20	Ayahuasca enhances creative divergent thinking while decreasing conventional convergent thinking. Psychopharmacology, 2016, 233, 3395-3403.	1.5	125
21	Neurophysiological evidence of impaired self-monitoring in schizotypal personality disorder and its reversal by dopaminergic antagonism. NeuroImage: Clinical, 2016, 11, 770-779.	1.4	25
22	Antidepressant Effects of a Single Dose of Ayahuasca in Patients With Recurrent Depression. Journal of Clinical Psychopharmacology, 2016, 36, 77-81.	0.7	364
23	Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years. Therapeutic Advances in Psychopharmacology, 2016, 6, 193-213.	1.2	204
24	Inhibition of alpha oscillations through serotonin-2A receptor activation underlies the visual effects of ayahuasca in humans. European Neuropsychopharmacology, 2016, 26, 1161-1175.	0.3	123
25	Naltrexone but Not Ketanserin Antagonizes the Subjective, Cardiovascular, and Neuroendocrine Effects of Salvinorin-A in Humans. International Journal of Neuropsychopharmacology, 2016, 19, pyw016.	1.0	25
26	Ayahuasca: Pharmacology, neuroscience and therapeutic potential. Brain Research Bulletin, 2016, 126, 89-101.	1.4	135
27	Exploring the therapeutic potential of Ayahuasca: acute intake increases mindfulness-related capacities. Psychopharmacology, 2016, 233, 823-829.	1.5	134
28	Ayahuasca Alters Structural Parameters of the Rat Aorta. Journal of Cardiovascular Pharmacology, 2015, 66, 58-62.	0.8	7
29	Neurophysiological Evidence of Compensatory Brain Mechanisms in Early-Stage Multiple Sclerosis. PLoS ONE, 2015, 10, e0136786.	1.1	31
30	New World Tryptamine Hallucinogens and the Neuroscience of Ayahuasca. Current Topics in Behavioral Neurosciences, 2015, , 1.	0.8	20
31	Long-term use of psychedelic drugs is associated with differences in brain structure and personality in humans. European Neuropsychopharmacology, 2015, 25, 483-492.	0.3	145
32	Evaluation of multiple comparison correction procedures in drug assessment studies using LORETA maps. Medical and Biological Engineering and Computing, 2015, 53, 1011-1023.	1.6	11
33	Salvinorin-A Induces Intense Dissociative Effects, Blocking External Sensory Perception and Modulating Interoception and Sense of Body Ownership in Humans. International Journal of Neuropsychopharmacology, 2015, 18, pyv065.	1.0	46
34	Serotonergic Psychedelics Temporarily Modify Information Transfer in Humans. International Journal of Neuropsychopharmacology, 2015, 18, .	1.0	67
35	Telling true from false: cannabis users show increased susceptibility to false memories. Molecular Psychiatry, 2015, 20, 772-777.	4.1	30
36	Metabolism and urinary disposition of <i>N</i> , <i>N</i> â€dimethyltryptamine after oral and smoked administration: a comparative study. Drug Testing and Analysis, 2015, 7, 401-406.	1.6	67

#	Article	IF	CITATIONS
37	Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a preliminary report. Revista Brasileira De Psiquiatria, 2015, 37, 13-20.	0.9	341
38	Apathy in Parkinson's Disease: Neurophysiological Evidence of Impaired Incentive Processing. Journal of Neuroscience, 2014, 34, 5918-5926.	1.7	55
39	Assessment of the Psychotherapeutic Effects of Ritual Ayahuasca Use on Drug Dependency: A Pilot Study. , 2014, , 183-196.		18
40	Ayahuasca and the Treatment of Drug Addiction. , 2014, , 95-109.		25
41	Acute effects of ayahuasca on neuropsychological performance: differences in executive function between experienced and occasional users. Psychopharmacology, 2013, 230, 415-424.	1.5	71
42	Methodology for determining major constituents of ayahuasca and their metabolites in blood. Biomedical Chromatography, 2012, 26, 301-313.	0.8	41
43	Personality, Psychopathology, Life Attitudes and Neuropsychological Performance among Ritual Users of Ayahuasca: A Longitudinal Study. PLoS ONE, 2012, 7, e42421.	1.1	202
44	4-Bromo-2,5-dimethoxyphenethylamine (2C-B): presence in the recreational drug market in Spain, pattern of use and subjective effects. Journal of Psychopharmacology, 2012, 26, 1026-1035.	2.0	92
45	Metabolism and disposition of <i>N</i> , <i>N</i> â€dimethyltryptamine and harmala alkaloids after oral administration of ayahuasca. Drug Testing and Analysis, 2012, 4, 610-616.	1.6	68
46	Pharmacology of ayahuasca administered in two repeated doses. Psychopharmacology, 2012, 219, 1039-1053.	1.5	108
47	Characterization of the cerebral activity by time–frequency representation of evoked EEG potentials. Physiological Measurement, 2011, 32, 1327-1346.	1.2	9
48	Methodology for and the determination of the major constituents and metabolites of the Amazonian botanical medicine ayahuasca in human urine. Biomedical Chromatography, 2011, 25, 970-984.	0.8	35
49	Autonomic, Neuroendocrine, and Immunological Effects of Ayahuasca. Journal of Clinical Psychopharmacology, 2011, 31, 717-726.	0.7	109
50	An fMRI Study on the Role of Serotonin in Reactive Aggression. PLoS ONE, 2011, 6, e27668.	1.1	53
51	A neuroimaging study of conflict during word recognition. NeuroReport, 2010, 21, 741-745.	0.6	2
52	Drug effect on EEG connectivity assessed by linear and nonlinear couplings. Human Brain Mapping, 2010, 31, 487-497.	1.9	33
53	Assessment of addiction severity among ritual users of ayahuasca. Drug and Alcohol Dependence, 2010, 111, 257-261.	1.6	179
54	Syllable congruency and word frequency effects on brain activation. Human Brain Mapping, 2009, 30, 3079-3088.	1.9	43

#	Article	IF	CITATIONS
55	Daytime Ayahuasca administration modulates REM and slow-wave sleep in healthy volunteers. Psychopharmacology, 2008, 196, 315-326.	1.5	48
56	Dopamine Agonist Increases Risk Taking but Blunts Reward-Related Brain Activity. PLoS ONE, 2008, 3, e2479.	1.1	134
57	Pattern of use and subjective effects of Salvia divinorum among recreational users. Drug and Alcohol Dependence, 2006, 85, 157-162.	1.6	168
58	Influence of individual differences in Behavioral Inhibition System on the magnitude and time course of the fear-potentiated startle. International Journal of Psychophysiology, 2006, 60, 323-329.	0.5	6
59	Increased frontal and paralimbic activation following ayahuasca, the pan-amazonian inebriant. Psychopharmacology, 2006, 186, 93-98.	1.5	200
60	Quantifying Drug-Drug Interactions in Pharmaco-EEG. Clinical EEG and Neuroscience, 2006, 37, 108-120.	0.9	9
61	A neurophysiological study of the detrimental effects of alprazolam on human action monitoring. Cognitive Brain Research, 2005, 25, 554-565.	3.3	57
62	Noradrenergic Stimulation Enhances Human Action Monitoring. Journal of Neuroscience, 2005, 25, 4370-4374.	1.7	74
63	Bringing Ayahuasca to the Clinical Research Laboratory. Journal of Psychoactive Drugs, 2005, 37, 219-230.	1.0	45
64	Effects of the South American Psychoactive Beverage <i>Ayahuasca </i> on Regional Brain Electrical Activity in Humans: A Functional Neuroimaging Study Using Low-Resolution Electromagnetic Tomography. Neuropsychobiology, 2004, 50, 89-101.	0.9	107
65	Human Pharmacology of Ayahuasca: Subjective and Cardiovascular Effects, Monoamine Metabolite Excretion, and Pharmacokinetics. Journal of Pharmacology and Experimental Therapeutics, 2003, 306, 73-83.	1.3	285
66	Effects of ayahuasca on sensory and sensorimotor gating in humans as measured by P50 suppression and prepulse inhibition of the startle reflex, respectively. Psychopharmacology, 2002, 165, 18-28.	1.5	61
67	Topographic pharmaco-EEG mapping of the effects of the South American psychoactive beverage ayahuasca in healthy volunteers. British Journal of Clinical Pharmacology, 2002, 53, 613-628.	1.1	108
68	Determination of N,N-dimethyltryptamine and β-carboline alkaloids in human plasma following oral administration of Ayahuasca. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2002, 779, 271-281.	1.2	72
69	Psychometric assessment of the Hallucinogen Rating Scaleâ [~] †. Drug and Alcohol Dependence, 2001, 62, 215-223.	1.6	67
70	Subjective effects and tolerability of the South American psychoactive beverage Ayahuasca in healthy volunteers. Psychopharmacology, 2001, 154, 85-95.	1.5	235
71	Differential effects of alprazolam on the baseline and fear-potentiated startle reflex in humans: a dose-response study. Psychopharmacology, 2001, 157, 358-367.	1.5	54
72	Effects of alprazolam on the acoustic startle response in humans. Psychopharmacology, 1999, 143, 280-285.	1.5	38